thiazol-5-ylmethyl ((2R,5R)-5-((S)-2-amino-3-methoxypropanamido)-1,6-diphenylhexan-2-yl)carbamate | 1004318-05-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: thiazol-5-ylmethyl ((2R,5R)-5-((S)-2-amino-3-methoxypropanamido)-1,6-diphenylhexan-2-yl)carbamate
• CAS: 1004318-05-1
• 化学式: C₂₇H₃₄N₄O₄S
• 分子量: 510.657
• InChiKey: RQNGACYGXIHZJZ-OYRHQHFDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.46
• 重原子数：
  36.0
• 可旋转键数：
  14.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  115.57
• 氢给体数：
  3.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  thiazol-5-ylmethyl ((2R,5R)-5-((S)-2-amino-3-methoxypropanamido)-1,6-diphenylhexan-2-yl)carbamate 、 2-异丙基-4-(甲基氨基甲基)噻唑 在 N,N-二异丙基乙胺 、 N,N'-羰基二咪唑 作用下， 生成 thiazol-5-ylmethyl N-[(1R,4R)-1-benzyl-4-[[(2S)-2-[[(2-isopropylthiazol-4-yl)methyl-methyl-carbamoyl]amino]-3-methoxy-propanoyl]amino]-5-phenyl-pentyl]carbamate
  参考文献：
  名称：

  Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350)

  摘要：

  The HIV protease inhibitor (PI) ritonavir (RTV) has been widely used as a pharmacoenhancer for other PIs, which are substrates of cytochrome P450 3A (CYP3A). However the potent anti-HIV activity of ritonavir may limit its use as a pharmacoenhancer with other classes of anti-HIV agents. Ritonavir is also associated with limitations such as poor physicochemical properties. To address these issues a series of compounds with replacements at the P2 and/or P3 region was designed and evaluated as novel CYP3A inhibitors. Through these efforts, a potent and selective inhibitor of CYP3A, GS-9350 (cobicistat) with improved physiochemical properties was discovered. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.057
• 作为产物：
  描述：

  tert-butyl N-[(2S)-1-[[(2R,5R)-1,6-diphenyl-5-(1,3-thiazol-5-ylmethoxycarbonylamino)hexan-2-yl]amino]-3-methoxy-1-oxopropan-2-yl]carbamate 生成 thiazol-5-ylmethyl ((2R,5R)-5-((S)-2-amino-3-methoxypropanamido)-1,6-diphenylhexan-2-yl)carbamate
  参考文献：
  名称：

  Structure–activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350)

  摘要：

  The HIV protease inhibitor (PI) ritonavir (RTV) has been widely used as a pharmacoenhancer for other PIs, which are substrates of cytochrome P450 3A (CYP3A). However the potent anti-HIV activity of ritonavir may limit its use as a pharmacoenhancer with other classes of anti-HIV agents. Ritonavir is also associated with limitations such as poor physicochemical properties. To address these issues a series of compounds with replacements at the P2 and/or P3 region was designed and evaluated as novel CYP3A inhibitors. Through these efforts, a potent and selective inhibitor of CYP3A, GS-9350 (cobicistat) with improved physiochemical properties was discovered. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.057